# Technology Appraisal Committee Meeting (Committee A)

**Minutes:** Unconfirmed  

**Date and Time:** Tuesday 19th January 2016, 10.00am – 2.00pm  

**Venue:** Prospero House  
241 Borough High Street  
London  
SE1 1GA

### Present:

1. Dr Jane Adam (Chair) Present for all notes  
2. Professor Iain Squire (Vice-Chair) Present for all notes  
3. Dr Mohit Misra Present for all notes  
4. Dr Jeremy Braybrooke Present for all notes  
5. Dr Gerardine Bryant Present for all notes  
6. Dr Nerys Woolacott Present for all notes  
7. Dr Brian Shine Present for all notes  
8. Mr David Thomson Present for all notes  
9. Dr Justin Daniels Present for all notes  
10. Dr Andrew England Present for all notes  
11. Dr Paul Robinson Present for all notes  
12. Dr Graham Ash Present for all notes  
13. Mr Stephen Sharp Present for all notes

### In attendance:

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meindert Boysen</td>
<td>Programme Director, National Institute for Health and Care Excellence</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Janet Robertson</td>
<td>Associate Director, National Institute for Health and Care Excellence</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Bijal Joshi</td>
<td>Project Manager, National Institute for Health and Care Excellence</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Zoe Charles</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>Present for all notes</td>
</tr>
</tbody>
</table>

### Non-public observers:

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua South</td>
<td>Coordinator, National Institute for Health and Care Excellence</td>
<td>Present for notes all notes</td>
</tr>
<tr>
<td>Ria Skelton</td>
<td>Editor, National Institute for Health and Care Excellence</td>
<td>Present for notes all notes</td>
</tr>
<tr>
<td>Dr Rosie Benneyworth</td>
<td>Non-Executive member, National Institute for Health and Care Excellence</td>
<td>Present for notes all notes</td>
</tr>
<tr>
<td>Dr Rachel Squires</td>
<td>Fellow, National Institute</td>
<td>Present for notes all notes</td>
</tr>
</tbody>
</table>
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisal of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [ID468].

2. Apologies were received from Professor John McMurray, Mrs Pamela Rees, Professor Aileen Clarke, Dr Rachel Hobson, Dr Anne McCune, Professor Olivia Wu, Ms Ellen Rule, Mrs Sarah Parry, and Dr John Watkins.

Any other Business

3. None

Notes from the last meeting

4. The minutes were agreed.

Appraisal of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [ID468]

Part 1 – Open session

5. The Chair welcomed the invited experts: Dr Steve Edwards and Ms Samantha Barton to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from PharmaMar to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Dr Jane Adam, Professor Iain Squire, Dr Mohit Misra, Dr Jeremy Braybrooke, Dr Gerardine Bryant, Dr Nerys Woolacott, Dr Brian Shine, Mr David Thomson, Dr Justin Daniels, Dr Andrew England, Dr Paul Robinson, Dr Graham Ash, and Mr Stephen Sharp all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [ID468].

7.2. Mr Adrian Griffin declared a non-personal specific financial interest as he is employed by Johnson and Johnson whom are a comparator company in the appraisal.

7.2.1 It was agreed that this declaration would prevent Dr Adrian Griffin from participating in this section of the meeting.

8. The Chair asked all NICE Staff to declare any relevant interests.
8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [ID468]

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [ID468]

10. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

11. The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [ID468] on the basis of the evidence before them.

12. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

13. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

14. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

15. The Committee continued to discuss the clinical and cost effectiveness of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [ID468].

16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

17. Tuesday 16th February 2016, from 10.0am – 5.00pm at Prospero House, 241 Borough High Street, London SE1 1GA.